Please login to the form below

Not currently logged in
Email:
Password:

XenoPort

This page shows the latest XenoPort news and features for those working in and with pharma, biotech and healthcare.

Reckitt Benckiser confirms pharma spin-off plans

Reckitt Benckiser confirms pharma spin-off plans

called arbaclofen placarbil - which was licensed in May from XenoPort.

Latest news

  • Publicis adds Heartbeat to portfolio Publicis adds Heartbeat to portfolio

    Clients included Galderma, Janssen Pharmaceuticals, Novartis, Pfizer, Sanofi, Teva and XenoPort. .

  • US shortage of GSK’s restless legs syndrome treatment Horizant US shortage of GSK’s restless legs syndrome treatment Horizant

    In its notice, the US regulator said GSK is “experiencing a backorder situation”, leaving an expected shortage of Horizant (gabapentin enacarbil) until June 2013 – one month after XenoPort assumes responsibility for ... Then in November 2012, GSK

  • GSK Restless Legs Syndrome drug approved

    GlaxoSmithKline and XenoPort have won marketing approval from the US Food and Drug Administration for Horizant, a treatment for moderate-to-severe primary Restless Legs Syndrome. ... The drug, which was discovered and developed by XenoPort, is converted

  • GSK migraine study fails

    A phase IIb clinical study of a migraine prophylaxis being developed by GlaxoSmithKline through a partnership with XenoPort failed to show that the drug was better than placebo at preventing headaches, ... GSK and XenoPort hypothesized that the failure

  • FDA rejects GSK and Xenoport's Horizant

    GSK and XenoPort, have received a Complete Response letter from the US FDA relating to Horizant (gabapentin enacarbil). ... GSK and Xenoport are evaluating the Complete Response letter and will communicate their intended next steps to the FDA.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    399-616. Xenoport/ Arbor Pharmaceuticals. Corporate acquisition. Acquisition for $7.03 per share [60% premium]; includes Horizant [gabapentin] for restless legs.

  • Deal Watch March 2016 Deal Watch March 2016

    Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – development. $595. Xenoport/ Dr Reddy's. XP-23829 for

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    260+. Xenoport / Reckitt Benckiser. Development and commercialisation licence. Arbaclofen placarbil end pIIa for alcohol use disorders.

  • Pharma deals during May 2014 Pharma deals during May 2014

    It is therefore very surprising that this month Reckitt Benckiser announced two deals relating to addiction products: a $145m deal with Xenoport for arbaclofen placarbil at end phase IIa for treatment ... In addition to the Xenoport deal reported above,

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • XenoPort appoints chief medical officer XenoPort appoints chief medical officer

    Richard Kim led Tysabri programme at Biogen Idec. XenoPort has appointed Dr Richard Kim as chief medical officer and senior VP, clinical development and medical affairs. ... He joined XenoPort from Biogen Idec where he was joint programme team leader for

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics